[Current treatment of carcinoid tumor].
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002275:Carcinoid Heart Disease / Q000188:drug therapy; D002276:Carcinoid Tumor / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D004041:Dietary Fats / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D004724:Endoscopy; D005770:Gastrointestinal Neoplasms / Q000235:genetics / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D016031:Liver Transplantation; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy / Q000517:prevention & control; D009362:Neoplasm Metastasis; D009525:Niacin / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015043:Zollinger-Ellison Syndrome / Q000150:complications
D000970:Antineoplastic Agents; D004041:Dietary Fats; D010456:Peptides, Cyclic; D012702:Serotonin Antagonists; C060347:lanreotide; D009525:Niacin; D013004:Somatostatin; D015282:Octreotide
Tratamiento actual del tumor carcinoide.